Summary
Ion mobility-high resolution mass spectrometry (IM-HRMS) is the next-generation analytical platform in research and industry. Unlocking its full potential across applications as varied as biotherapeutics, environment and food safety requires not only pushing back the frontiers of instrumentation, fundamental understanding and applications – but harmonisation is essential. To achieve this, current shortcomings in data collection, analysis and reporting across instrument types, laboratories and research areas need to be scrutinised and overcome.
The MobiliTraIN Doctoral Network will form 10 Doctoral Candidates (DCs) who will bring a new fundamental understanding of IM-HRMS, provide reference materials and guidelines for standardisation, develop state-of-the-art methods for the application of IM-HRMS in biopharmaceutical development, biological ‘omics studies, and nontarget screening of contaminants, and lay the foundations for IM-HRMS adoption in industry. Through an interdisciplinary research programme, including an open science approach and training in technical, business and transferable skills, the MobiliTraIN DCs will become leading experts in ion mobility with a unique skill set to successfully advance their careers while supporting Europe’s innovation capacity.
Building on existing collaborations and research excellence covering the entire innovation chain of IM-HRMS development and application, MobiliTraIN unites 8 academic institutions, 3 leading instrumentation companies, 1 regulatory agency, 1 pharma industry leader and 5 SMEs from 8 countries. With complementary expertise, know-how and mentoring experience, our consortium is ideally suited to unveil the potential of IM-HRMS as a key technology for safer therapeutics, better understanding of complex disease progression and improved monitoring of food, water and public health safety.
The MobiliTraIN Doctoral Network will form 10 Doctoral Candidates (DCs) who will bring a new fundamental understanding of IM-HRMS, provide reference materials and guidelines for standardisation, develop state-of-the-art methods for the application of IM-HRMS in biopharmaceutical development, biological ‘omics studies, and nontarget screening of contaminants, and lay the foundations for IM-HRMS adoption in industry. Through an interdisciplinary research programme, including an open science approach and training in technical, business and transferable skills, the MobiliTraIN DCs will become leading experts in ion mobility with a unique skill set to successfully advance their careers while supporting Europe’s innovation capacity.
Building on existing collaborations and research excellence covering the entire innovation chain of IM-HRMS development and application, MobiliTraIN unites 8 academic institutions, 3 leading instrumentation companies, 1 regulatory agency, 1 pharma industry leader and 5 SMEs from 8 countries. With complementary expertise, know-how and mentoring experience, our consortium is ideally suited to unveil the potential of IM-HRMS as a key technology for safer therapeutics, better understanding of complex disease progression and improved monitoring of food, water and public health safety.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101119562 |
| Start date: | 01-02-2024 |
| End date: | 31-01-2028 |
| Total budget - Public funding: | - 2 716 898,00 Euro |
Cordis data
Original description
Ion mobility-high resolution mass spectrometry (IM-HRMS) is the next-generation analytical platform in research and industry. Unlocking its full potential across applications as varied as biotherapeutics, environment and food safety requires not only pushing back the frontiers of instrumentation, fundamental understanding and applications – but harmonisation is essential. To achieve this, current shortcomings in data collection, analysis and reporting across instrument types, laboratories and research areas need to be scrutinised and overcome.The MobiliTraIN Doctoral Network will form 13 Doctoral Candidates (DCs) who will bring a new fundamental understanding of IM-HRMS, provide reference materials and guidelines for standardisation, develop state-of-the-art methods for the application of IM-HRMS in biopharmaceutical development, biological ‘omics studies, and nontarget screening of contaminants, and lay the foundations for IM-HRMS adoption in industry. Through an interdisciplinary research programme, including an open science approach and training in technical, business and transferable skills, the MobiliTraIN DCs will become leading experts in ion mobility with a unique skill set to successfully advance their careers while supporting Europe’s innovation capacity.
Building on existing collaborations and research excellence covering the entire innovation chain of IM-HRMS development and application, MobiliTraIN unites 10 academic institutions, 3 leading instrumentation companies, 1 regulatory agency, 1 pharma industry leader and 5 SMEs from 8 countries. With complementary expertise, know-how and mentoring experience, our consortium is ideally suited to unveil the potential of IM-HRMS as a key technology for safer therapeutics, better understanding of complex disease progression and improved monitoring of food, water and public health safety.
Status
SIGNEDCall topic
HORIZON-MSCA-2022-DN-01-01Update Date
31-07-2023
Images
No images available.
Geographical location(s)
Search
Organisations
-
| UNIVERSITAET FUER BODENKULTUR WIEN (Coördinator)
-
| ACCELOPMENT AG
-
| Agilent Technologies, Inc.
-
| Analytisches Forschungsinstitut für Non-Target Screening GmbH (AFIN-TS)
-
| BUNDESANSTALT FUER MATERIALFORSCHUNG UND -PRUEFUNG
-
| Bruker Daltonics GmbH & Co. KG
-
| CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
-
| ECOLE NATIONALE VETERINAIRE, AGROALIMENTAIRE ET DE L'ALIMENTATION NANTES ATLANTIQUE
-
| FREIE UNIVERSITAET BERLIN
-
| Gilles Toussaint
-
| INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
-
| JANSSEN PHARMACEUTICA NV
-
| MICROMASS UK LTD
-
| Quality Assistance
-
| THE UNIVERSITY OF MANCHESTER